Understanding the Expanding Armamentarium for GIST

Slides:



Advertisements
Similar presentations
Update on GIST Research
Advertisements

Heinrich & Corless Laboratories GIST Research Updates: May 2011.
Fostering a Collaborative Approach in the Management of BRCA-Mutated Ovarian Cancer.
State of the Art in BRCA-Mutated Ovarian Cancer
Perspectives on Managing Polycythemia Vera for the Nurse Practitioner and Physician Assistant.
An Individual’s Right to Access and Obtain Their Health Information Under HIPAA.
Applying Biosimilars in Hematologic Cancers
Post-autologous Transplant Therapy for Hodgkin Lymphoma
Targeting FLT3 Mutations in Acute Myeloid Leukemia
Improving the Diagnosis and Treatment of Seizures in Long-term Care
Relapsed/Refractory Follicular Lymphoma Conundrums
What to Do Next: Sequencing of Therapy in Patients With Metastatic CRC
The ABCs of AF.
Progression After Cancer Immunotherapy in Advanced NSCLC
Metastatic Renal Cell Carcinoma
Hemophilia Updates: Incorporating New Concepts Into Practice
Extended Half-life Factor Products in the Management of Hemophilia
The Nurse View: Updates in the Management of Metastatic Colorectal Cancer.
Optimizing Outcomes in the Management of GIST
Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.
Treating Transplant-Ineligible Patients With Multiple Myeloma
Assessing Newer Treatment Approaches for Multiply Relapsed Multiple Myeloma.
Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.
Clinical Considerations in Evidence-based Management of GIST
THE CONTINUUM OF CARE IN mCRC: OPTIMIZING USE OF EGFR ANTIBODIES
Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma
Optimizing Management of Advanced Bladder Cancer
Best Practices in Metastatic Colorectal Cancer
Managing gBRCA-Positive Metastatic Breast Cancer
Individualizing Care in Ovarian Cancer
The future of urate-lowering strategies for gout
The Nurse View: Targeted Therapies for the Patient With Metastatic Colorectal Cancer.
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Practical Guidance on Using New Therapies for Relapsed/ Refractory Follicular Lymphoma and Chronic Lymphocytic Leukemia.
Evaluating Next-Generation BTK Inhibitors
Case Studies in Unresectable Hepatocellular Carcinoma
Gene Therapy: Past, Present, and Future
Mutational Testing to Select Novel Targeted Therapies in AML
Improving Therapeutic Management of Huntington's Disease in Long-Term Care.
How to Effectively Manage Patients With Cutaneous Squamous Cell Carcinoma.
How to Find and Participate in a GIST clinical trial
Advancing Care Across the Spectrum of Pancreatic Cancer
PARP Inhibitors and Ovarian Cancer: What Did Data From Washington, DC, Tell Us?
Treating CD30-Expressing Cutaneous T-Cell Lymphoma
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data.
Myeloid Updates From the Summer Congresses
Updates in the Management of Acute Promyelocytic Leukemia
Advances in Immunotherapy for Peanut Allergy
The Road to Quality Improvement in HER2-Positive Breast Cancer
Locally Advanced Lung Cancer
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Molecular Testing in Ovarian Cancer: Is the Time Now?
Extended Half-life Factor Products in the Management of Hemophilia
Program Goals Disclaimers Defining Refractory Seizures.
New ELN Recommendations
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
The Changing Field of Melanoma: Ipilimumab.
Fig. 5. Clinical data with BLU-285 confirm early evidence of activity in patients with diseases driven by KIT and PDGFRA activation loop mutations. Clinical.
VOD/SOS: Aligned Education for Patients and the Interprofessional Team
Practical Guidance on the Management of Pan-Negative NSCLC
THE CONTINUUM OF CARE IN mCRC: OPTIMIZING USE OF EGFR ANTIBODIES
The ABCs of AF.
Navigating New Treatment Landscapes in HR+ HER2-Negative Advanced Breast Cancer.
Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition
Tailoring Therapy in the Newly Diagnosed Patient With CLL
Optimizing Outcomes in Patients With NSCLC and Liver Metastases
Clinical Considerations in Evidence-based Management of GIST
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Exploring the Use of Adeno-Associated Virus for Gene Therapy
Optimizing Patient Outcomes in Metastatic Triple-Negative Breast Cancer.
Presentation transcript:

Understanding the Expanding Armamentarium for GIST

Overview of GIST

Workup of Suspected GIST

Initial Treatment of Metastatic GIST

First-Line GIST Treatment: Imatinib

Second-Line GIST Treatment: Sunitinib

Third-Line GIST Treatment: Regorafenib

Investigational Approaches: Crenolanib

CrenoGIST: Phase 3 Trial of Crenolanib in D842V-Mutated GIST

Investigational Approaches: Avapritinib

VOYAGER: Phase 3 Trial of Avapritinib in Third- and Fourth-Line GIST

Investigational Approaches: Ripretinib

Phase 3 Trials of Ripretinib in GIST

Other Novel Strategies

Key Takeaways

Abbreviations

Abbreviations (cont)